ArticleJournal of neuro-oncology2025
Impact of anti-seizure medication duration on postoperative seizures following supratentorial high-grade glioma resection: a mixed-model and tree-based approach.
Article in Journal of neuro-oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposePostoperative seizures are a significant complication following glioma surgery. While prophylactic antiseizure medications (ASMs) are widely prescribed, the optimal duration of prophylaxis remains unclear. Current guidelines lack specificity regarding high-risk subgroups that may benefit from extended ASM therapy. Here, we aimed to determine whether ASM duration affects postoperative seizure occurrence and to identify patient subgroups in whom longer ASM prophylaxis significantly reduces seizure risk.
methodsWe conducted a retrospective cohort study of 206 adult high-grade glioma patients who underwent resection. Postoperative seizure occurrence was the primary outcome. ASM duration was modeled using logistic regression with cubic splines to detect non-linear effects, and a classification decision tree was trained to identify high-risk subgroups. Observed seizure rates were compared across data-driven ASM duration thresholds. Time-to-event analysis was also performed.
resultsMean age was 48.1 years (SD 15.9); 48.5% were male. Most tumors were located in the frontal (43.3%) and temporal lobes (29.6%), with glioblastoma being the most common histology (65%). Spline regression revealed no statistically significant association between ASM duration and seizure occurrence (pseudo R² = 0.0066; p = 0.69). However, decision tree analysis suggested a clinically meaningful subgroup: patients aged > 52.5 years with subtotal resection had increased seizure risk when ASM duration was ≤ 135 days. In this group, extending ASM prophylaxis was associated with a lower seizure rate.
conclusionWhile extended ASM prophylaxis was not broadly associated with reduced seizure risk, tree-based analysis suggested an older, incompletely resected subgroup that may benefit from prolonged ASM use. REGISTRATION NUMBER: IR.TUMS.SINAHOSPITAL.REC.1402.091 retrospectively registered.
Indexed as
Identifiers
41432958What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.